StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) income statement

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.30−0.20 (-2.67%)

Close on Nov 18, 2026Market cap $1.87BP/E –Yield –

BioCryst Pharmaceuticals Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
97.8%
Operating margin
-33.3%
Net margin
-40.9%
Return on equity, FY2025
-88.7%

Financial strength

Current ratio
2.32
Debt to equity
-0.87
Debt to assets
70.9%
Cash to current liabilities
74.2%

Valuation

P/E ratio
–
Price to sales
1.98
Price to book
–
Dividend yield
–

See a number that looks wrong?